EA201791112A1 - Новые связывающиеся с pd-l1 полипептиды для визуализации - Google Patents

Новые связывающиеся с pd-l1 полипептиды для визуализации

Info

Publication number
EA201791112A1
EA201791112A1 EA201791112A EA201791112A EA201791112A1 EA 201791112 A1 EA201791112 A1 EA 201791112A1 EA 201791112 A EA201791112 A EA 201791112A EA 201791112 A EA201791112 A EA 201791112A EA 201791112 A1 EA201791112 A1 EA 201791112A1
Authority
EA
Eurasian Patent Office
Prior art keywords
visualization
polypeptides
new bonding
new
bonding
Prior art date
Application number
EA201791112A
Other languages
English (en)
Other versions
EA037590B1 (ru
Inventor
Пол Е. Морин
Дэвид Доннелли
Даса Липовсек
Йохем Гокемайер
Мариа Н. Джуре-Кункел
Давид Фабрицио
Мартин С. Райт
Дуглас Дисчино
Сэмюэл Дж. Бонакорси
Ральф Адам Смит
Вирджини Лафонт
Дэниэл Кохен
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201791112A1 publication Critical patent/EA201791112A1/ru
Publication of EA037590B1 publication Critical patent/EA037590B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В данном документе представлены новыеFn3 домены, которые специфично связываются с PD-L1, а также визуализирующие средства на их основе для диагностики.
EA201791112A 2014-11-25 2015-11-24 Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации EA037590B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462084298P 2014-11-25 2014-11-25
PCT/US2015/062485 WO2016086021A1 (en) 2014-11-25 2015-11-24 Novel pd-l1 binding polypeptides for imaging

Publications (2)

Publication Number Publication Date
EA201791112A1 true EA201791112A1 (ru) 2017-10-31
EA037590B1 EA037590B1 (ru) 2021-04-19

Family

ID=54834952

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791112A EA037590B1 (ru) 2014-11-25 2015-11-24 Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации

Country Status (14)

Country Link
US (3) US10406251B2 (ru)
EP (2) EP3702367B1 (ru)
JP (2) JP6622814B2 (ru)
KR (1) KR102632418B1 (ru)
CN (2) CN114591420A (ru)
AU (1) AU2015353573B2 (ru)
BR (1) BR112017010137A2 (ru)
CA (1) CA2969067A1 (ru)
EA (1) EA037590B1 (ru)
ES (1) ES2822990T3 (ru)
IL (1) IL252354B (ru)
MX (1) MX2017006530A (ru)
SG (1) SG11201703760WA (ru)
WO (1) WO2016086021A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102494646B1 (ko) 2014-03-20 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 안정화된 피브로넥틴 기반 스캐폴드 분자
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
KR102632418B1 (ko) 2014-11-25 2024-01-31 브리스톨-마이어스 스큅 컴퍼니 영상화를 위한 신규 pd-l1 결합 폴리펩티드
US11229713B2 (en) * 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
LT3458111T (lt) * 2016-05-19 2021-05-25 Bristol-Myers Squibb Company Pet vizualizacijos imunomoduliatoriai
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
EP3463486A1 (en) * 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
EP3932432A1 (en) 2016-12-14 2022-01-05 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
CA3048229A1 (en) 2016-12-23 2018-06-28 The Johns Hopkins University Tumor and immune cell imaging based on pd-l1 expression
JP7167041B2 (ja) 2017-02-10 2022-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
CN108503691B (zh) * 2017-02-25 2021-07-23 复旦大学 一种人pd-l1蛋白高亲和性肽及其应用
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CN110891614A (zh) 2017-05-05 2020-03-17 融合制药公司 Igf-1r单克隆抗体及其用途
WO2018204869A1 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
EP3642220A1 (en) 2017-06-23 2020-04-29 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
KR20200031645A (ko) 2017-07-24 2020-03-24 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
US20190099506A1 (en) 2017-10-02 2019-04-04 Bristol-Myers Squibb Company Methods and compositions for deuterated biologics
CN111051332A (zh) 2017-10-03 2020-04-21 百时美施贵宝公司 免疫调节剂
US11858960B2 (en) 2018-03-01 2024-01-02 Vrije Universiteit Brussel Human PD-L1-binding immunoglobulins
US11987629B2 (en) 2018-06-01 2024-05-21 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
WO2020001526A1 (zh) * 2018-06-29 2020-01-02 苏州智核生物医药科技有限公司 Pd-l1结合多肽及其用途
CN109991843B (zh) * 2019-04-30 2021-11-23 广州齐志生物工程设备有限公司 一种生物反应器的温度控制方法
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
CN116568341A (zh) 2020-02-28 2023-08-08 百时美施贵宝公司 基于纤连蛋白的放射性标记的支架和抗体及其治疗诊断用途
US20230235007A1 (en) * 2020-06-15 2023-07-27 Ming-Che Shih Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
CN113509562B (zh) * 2021-04-22 2023-04-07 苏州智核生物医药科技有限公司 包含pd-l1结合多肽组合物的制剂及其制备方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
WO1995017886A1 (en) 1993-12-27 1995-07-06 Baxter International Inc. Water soluble non-immunogenic polyamide cross-linking agents
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6548530B1 (en) 1995-10-03 2003-04-15 The Scripps Research Institute CBI analogs of CC-1065 and the duocarmycins
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP4118462B2 (ja) 1999-07-19 2008-07-16 株式会社リコー 携帯電子機器
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
CA2443332A1 (en) 2001-04-04 2002-10-17 University Of Rochester .alpha..nu..beta.3 integrin-binding polypeptide monobodies and their use
IL154183A0 (en) 2001-05-31 2003-07-31 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
PT2316852E (pt) 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
CA2525553C (en) 2003-05-14 2011-07-05 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
CN1938046B (zh) 2003-11-06 2014-03-19 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
PT2161336E (pt) 2005-05-09 2013-10-03 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
PL1940789T3 (pl) 2005-10-26 2012-04-30 Squibb & Sons Llc Metody i związki do otrzymywania analogów cc-1065
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
AR062448A1 (es) 2006-05-25 2008-11-12 Endocyte Inc Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
JP5537946B2 (ja) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Ｉｇｆ−ｉｒを含むチロシンキナーゼ受容体に対する改変タンパク質に基づく標的治療薬
EP2111237B1 (en) 2006-12-11 2015-03-18 BRACCO IMAGING S.p.A. Fibrin-binding peptides and conjugates thereof
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
CA2678514A1 (en) 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
EP2036576A1 (en) 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs
JP2011503000A (ja) 2007-11-02 2011-01-27 セントコア・オーソ・バイオテツク・インコーポレーテツド 半合成ＧＬＰ−１ペプチド−Ｆｃ融合コンストラクト、その方法及び使用
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
EP2234646A2 (en) 2007-12-27 2010-10-06 Novartis AG Improved fibronectin-based binding molecules and their use
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
PL2439212T3 (pl) 2008-05-02 2017-06-30 Novartis Ag Ulepszone cząsteczki wiążące na bazie fibronektyny oraz ich zastosowanie
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US9217210B2 (en) 2009-03-24 2015-12-22 North Carolina State University Process of making composite inorganic/polymer nanofibers
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
PE20130238A1 (es) 2010-04-13 2013-03-11 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina que se unen a la proproteina convertasa subtilisina kexina tipo 9 (pcsk9)
WO2011130613A1 (en) 2010-04-15 2011-10-20 Seattle Genetics, Inc. Targeted pyrrolobenzodiazapine conjugates
EP2558475A1 (en) 2010-04-15 2013-02-20 Spirogen Sàrl Pyrrolobenzodiazepines used to treat proliferative diseases
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
LT2697257T (lt) 2011-04-13 2016-12-27 Bristol-Myers Squibb Company Su fc sulieti baltymai, apimantys naujus linkerius ir išsidėstimus
RU2016147206A (ru) * 2011-04-15 2018-10-19 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
WO2013010573A1 (en) 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
EP2751120B1 (en) 2011-09-20 2018-08-22 MedImmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CN104220441B (zh) 2012-02-13 2017-03-29 百时美施贵宝公司 烯二炔化合物、其缀合物及其用途和方法
US9212224B2 (en) * 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104736168B (zh) * 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
TWI694085B (zh) 2012-09-13 2020-05-21 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
ES2755804T3 (es) 2012-12-03 2020-04-23 Curasight Aps Péptidos marcados con un radionúclido que emite positrones para obtención de imágenes de PET del uPAR humana
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
WO2014126836A1 (en) 2013-02-14 2014-08-21 Bristol-Myers Squibb Company Tubulysin compounds, methods of making and use
CN105377287A (zh) 2013-02-15 2016-03-02 托马斯杰弗逊大学 用于肿瘤成像的试剂盒
US9433689B2 (en) 2013-03-12 2016-09-06 The Board Of Trustees Of The Leland Stanford Junio Probes and methods of imaging non-Hodgkins lymphoma
WO2015073746A2 (en) 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research 18f labeling of proteins using sortases
KR102494646B1 (ko) 2014-03-20 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 안정화된 피브로넥틴 기반 스캐폴드 분자
EP3129401B1 (en) 2014-03-20 2019-06-12 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
CN106573916A (zh) 2014-06-09 2017-04-19 武田药品工业株式会社 放射性标记的化合物
US9546206B2 (en) 2014-08-08 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University High affinity PD-1 agents and methods of use
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
KR102632418B1 (ko) 2014-11-25 2024-01-31 브리스톨-마이어스 스큅 컴퍼니 영상화를 위한 신규 pd-l1 결합 폴리펩티드
US11229713B2 (en) 2014-11-25 2022-01-25 Bristol-Myers Squibb Company Methods and compositions for 18F-radiolabeling of biologics
EP3280455A1 (en) 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Non-invasive imaging of tumor pd-l1 expression
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
EP3733698A1 (en) 2015-09-23 2020-11-04 Bristol-Myers Squibb Company Glypican-3 binding fibronectin based scafflold molecules
US11155596B2 (en) 2015-10-30 2021-10-26 Affibody Ab Polypeptide
JP6990652B2 (ja) 2015-10-30 2022-02-03 アフィボディ・アーベー 新規ポリペプチド
AU2017206445B2 (en) 2016-01-15 2019-07-18 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18F-labled active site inhibited factor VII
EP3463486A1 (en) 2016-06-01 2019-04-10 Bristol-Myers Squibb Company Pet imaging with pd-l1 binding polypeptides
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics

Also Published As

Publication number Publication date
JP7127008B6 (ja) 2023-12-22
EP3224277B1 (en) 2020-08-26
SG11201703760WA (en) 2017-06-29
EA037590B1 (ru) 2021-04-19
US20220001040A1 (en) 2022-01-06
US10406251B2 (en) 2019-09-10
US20170258948A1 (en) 2017-09-14
JP2020048567A (ja) 2020-04-02
JP6622814B2 (ja) 2019-12-18
CN114591420A (zh) 2022-06-07
ES2822990T3 (es) 2021-05-05
IL252354A0 (en) 2017-07-31
CN107406494A (zh) 2017-11-28
EP3224277A1 (en) 2017-10-04
IL252354B (en) 2021-07-29
EP3702367A1 (en) 2020-09-02
BR112017010137A2 (pt) 2018-02-06
EP3702367B1 (en) 2024-05-15
MX2017006530A (es) 2017-08-10
CA2969067A1 (en) 2016-06-02
WO2016086021A1 (en) 2016-06-02
KR102632418B1 (ko) 2024-01-31
CN107406494B (zh) 2022-03-25
JP7127008B2 (ja) 2022-08-29
AU2015353573B2 (en) 2020-09-03
AU2015353573A1 (en) 2017-05-25
JP2018508213A (ja) 2018-03-29
US20190343972A1 (en) 2019-11-14
KR20170085588A (ko) 2017-07-24
US11173219B2 (en) 2021-11-16

Similar Documents

Publication Publication Date Title
EA201791112A1 (ru) Новые связывающиеся с pd-l1 полипептиды для визуализации
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2016002455A1 (es) Anticuerpos multiespecíficos.
DK3389682T3 (da) Gruppe b-adenovirus, der koder for et anti-tcr-kompleks-antistof eller -fragment
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
TR201905829T4 (tr) Buzdolabı.
TR201909606T4 (tr) Pi̇razollari hazirlamak i̇çi̇n i̇şlem
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
UY34885A (es) Proteínas de unión anti-mesotelina
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2023006416A (es) Anticuerpos, usos y metodos.
GB2548503B (en) System for generating an output file
TR201819099T4 (tr) Besleme malzemenin işlenmesi için düzenek ve yöntem.
CL2015002358A1 (es) Compuestos bicíclicos.
CL2017002255A1 (es) Procesos para preparar fluorocetólidos.
BR112016027455A2 (pt) moduladores ppar
TR201909125T4 (tr) Yüzey temi̇zlemek i̇çi̇n bi̇r aparat